PREA and BPCA: Spurring Pediatric Drug Development
The Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA), permanently reauthorized in 2012, work together to foster pediatric drug development, creating a balanced approach that generates important safety and efficacy information on use of medicines in children and enables biopharmaceutical companies to continue to make significant investments in pediatric drug research.
Related Resources
